vzphotos There’s no sugarcoating the fact that AbbVie (NYSE:ABBV), the biggest healthcare stock by market capitalisation after Eli Lilly and Company (LLY), has seen dismal full-year results for 2023 last month with a 6.4% decline in revenue and a huge 59% drop in reported earnings per share [EPS]. Still, its price is on the up and up. Year-to-date [YTD], its price has risen by over 15%. To contextualise, the S&P 500 Health Care Index is up by less than half this at 7.1%. With this disconnect between fun ...

Last year emerged as a time of unexpected resilience and expansion for the stock market driven by the strength of unstoppable mega-cap stocks. Notably, the S&P 500 wrapped up last year with a solid 24% gain, turning heads in the process.Moreover, the stock market picked up from where it left off last year, taking things up a notch or two by hitting new highs several times in recent months. Central to this rally are mega-cap stocks, driving market indices to new heights on the back of the artificial intellig ...

Stocks have been off to a very bullish start in 2024, and investors seem increasingly optimistic about the overall state of the market and the global economy. Now, that's not to say there aren't still notable macroeconomic challenges that are creating a nuanced operating environment for companies across a range of industries and sectors.However, excellent businesses with long-term growth stories can stay above the fray. If you have some cash, say $2,500, to invest in stocks, here are two companies you might ...

Hailshadow Introduction The healthcare sector has always been fascinating to me. It combines innovative approaches that can achieve a significant premium for its products with essential products. Therefore, these companies tend to be more resilient to economic uncertainties. One such company is AbbVie (NYSE:ABBV), which I analyzed almost two years ago. I hold shares in the company in my dividend growth portfolio. The company is a leading pharmaceutical giant that had to deal with the loss of exclusivity ...

vzphotos Business Overview AbbVie Inc. (NYSE:ABBV) is a pharmaceutical with a strong history of growth and generating income for investors. In addition to having a number of highly lucrative products in the market such as Skyrizi and Rinvoq, the company also enjoys a pretty robust pipeline of many products in a variety of phases of development in several fields including oncology, immunology, and neuroscience. In 2025, the company expects to obtain FDA approval for a variety of products including Rinvoq for ...

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend yield, ...

The most recent trading session ended with AbbVie (ABBV) standing at $180.57, reflecting a -0.27% shift from the previouse trading day's closing. The stock trailed the S&P 500, which registered a daily gain of 1.03%. Elsewhere, the Dow saw an upswing of 0.34%, while the tech-heavy Nasdaq appreciated by 1.51%.Heading into today, shares of the drugmaker had gained 3.46% over the past month, outpacing the Medical sector's gain of 2.1% and the S&P 500's gain of 3.21% in that time.Investors will be eagerly watch ...

NORTH CHICAGO, Ill., March 7, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays 26th Annual Global Healthcare Conference on Thursday, March 14, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 8:00 a.m. Central time. A live a ...

Dividend Aristocrats are a rare group of stocks. Not only do these members of the S&P 500 pay shareholders a dividend but in order to make the cut, they need to have raised their payout at least yearly for 25 years or more. With thousands of stocks on the market, only a few dozen achieved this status. At last count, there are only 68 Dividend Aristocrats to buy.But just because a stock made the list doesn’t automatically mean you should buy it. Dividend Aristocrats can and do cut their payouts. Walgreens Bo ...

A total of 29 abstracts, including three late-breaking presentations, demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing science across a spectrum of immune-mediated dermatologic conditions and aesthetic indicationsNORTH CHICAGO, Ill., March 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Allergan Aesthetics, an AbbVie company, today announced they will present 29 abstracts, including three late-breaking presentations, during the 2024 American Academy of Dermatology (AAD) Annual Meet ...